Cullinan Therapeutics (CGEM) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

CGEM · Stock Price

USD 14.72+7.18 (+95.23%)

Market Cap: $897.2M

Historical price data

Market Cap: $897.2MPipeline: 10 drugsPatents: 1Founded: 2016Employees: 100-250HQ: Cambridge, United States

Sector Ranking#104 in Biologics / Biosimilars #182 in Small Molecule Drugs

Overview

Cullinan Therapeutics is a clinical-stage biopharma focused on translating deep immunology expertise into high-impact therapies for autoimmune diseases and cancer. The company employs a disciplined 'thriller or killer' portfolio strategy, yielding a focused pipeline of novel bispecific T cell engagers and kinase inhibitors. Recent milestones include completing a rolling NDA submission for zipalertinib in EGFR exon 20 NSCLC and reporting promising early clinical data for its bispecific candidates in hematology and autoimmune indications, positioning 2025 as a catalyst-rich year.

OncologyAutoimmune Diseases

Technology Platform

Cullinan's platform leverages deep immunology expertise to develop differentiated bispecific T cell engagers (engineered for high target affinity and extended half-life) and targeted small molecule kinase inhibitors.

Pipeline

10

10 drugs in pipeline

Drug	Indication	Stage
CLN-081	Non Small Cell Lung Cancer	Phase 1/2
VK-2019	Nasopharyngeal Carcinoma	Phase 1/2
CLN-978	Sjögren	Phase 1
CLN-978	SLE	Phase 1
CLN-619	Multiple Myeloma	Phase 1

Opportunities

Near-term opportunities include the potential FDA approval and commercial launch of zipalertinib in EGFR exon 20+ NSCLC, establishing a revenue base, and positive clinical proof-of-concept for CLN-978 in autoimmune diseases, which could unlock a transformative multi-billion dollar market.

The company's cash runway into 2027 provides stability to pursue these catalysts.

Risk Factors

Key risks include clinical failure of lead assets (particularly the high-stakes CLN-978 autoimmune data), regulatory setbacks for zipalertinib's NDA, and intense competition in both the niche NSCLC and broad autoimmune markets.

Execution risk in transitioning to a commercial company is also present.

Competitive Landscape

Zipalertinib competes with approved amivantamab and other exon 20 TKIs in NSCLC. CLN-978 faces competition from CD20 antibodies and emerging CD19 CAR-Ts in autoimmunity. CLN-049 enters a crowded AML field with targeted agents and other TCEs. Differentiation on efficacy, safety, and convenience is critical.